Chemistry:Bimekizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | IL17A, IL17F, IL17AF |
| Clinical data | |
| Trade names | Bimzelx |
| Other names | UCB4940, bimekizumab-bkzx |
| License data |
|
| Pregnancy category | |
| Routes of administration | Subcutaneous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6552H10132N1750O2029S42 |
| Molar mass | 147229.87 g·mol−1 |
Bimekizumab, sold under the brand name Bimzelx, is a humanized anti-IL17A, anti-IL-17F, and anti-IL17AF monoclonal antibody[5][6] that is used to treat plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, and ankylosing spondylitis.[5]
The most common side effects include upper respiratory tract infections (nose and throat infection) and oral candidiasis (thrush, a fungal infection in the mouth or throat).[5] Injection site reactions were also common, reported in 3% of subjects.[7]
Bimekizumab was approved for medical use in the European Union in August 2021,[5][8][9] and in the United States in October 2023.[10][11]
Medical uses
In the EU, bimekizumab is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, non-radiographic axial spondyloarthritis, and active ankylosing spondylitis.[5]
History
Bimekizumab is being developed by Belgian pharmaceutical company UCB.[citation needed]
Society and culture
Names
Bimekizumab is the international nonproprietary name (INN).[12]
Research
Phase III trials have demonstrated that bimekizumab is superior to not only adalimumab[13] but also secukinumab[14] and ustekinumab[15] for the treatment of plaque psoriasis.
References
- ↑ 1.0 1.1 "Bimzelx APMDS". 7 April 2022. https://www.tga.gov.au/resources/auspmd/bimzelx.
- ↑ "Updates to the Prescribing Medicines in Pregnancy database". 21 December 2022. https://www.tga.gov.au/resources/resource/guidance/updates-prescribing-medicines-pregnancy-database.
- ↑ "Bimzelx Product information". 25 April 2012. https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=101427.
- ↑ "Bimzelx- bimekizumab injection, solution". 20 October 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26b88358-871f-4c80-9d80-b2fb16477f81.
- ↑ 5.0 5.1 5.2 5.3 5.4 5.5 "Bimzelx EPAR". 23 June 2021. https://www.ema.europa.eu/en/medicines/human/EPAR/bimzelx. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ↑ "Systematic review of immunomodulatory therapies for hidradenitis suppurativa". Biologics: Targets & Therapy 13: 53–78. 13 May 2019. doi:10.2147/BTT.S199862. PMID 31190730.
- ↑ FDA Professional Drug Information
- ↑ "Bimzelx Product information". https://ec.europa.eu/health/documents/community-register/html/h1575.htm.
- ↑ "UCB Announces European Commission Approval of Bimzelx (bimekizumab) for the Treatment of Adults with Moderate to Severe Plaque Psoriasis". UCB (Press release). 24 August 2021. Archived from the original on 25 August 2021. Retrieved 24 August 2021.
- ↑ Frellick, Marcia (18 October 2023). "FDA Approves Bimekizumab for Plaque Psoriasis in Adults". https://www.medscape.com/viewarticle/997490.
- ↑ "Bimzelx Approved by the U.S. FDA for the Treatment of Adults with Moderate to Severe Plaque Psoriasis". UCB (Press release). 18 October 2023. Archived from the original on 28 October 2023. Retrieved 28 October 2023.
- ↑ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 72". WHO Drug Information 28 (3). 2014.
- ↑ "Bimekizumab versus Adalimumab in Plaque Psoriasis". The New England Journal of Medicine 385 (2): 130–141. July 2021. doi:10.1056/NEJMoa2102388. PMID 33891379.
- ↑ "Bimekizumab versus Secukinumab in Plaque Psoriasis". The New England Journal of Medicine 385 (2): 142–152. July 2021. doi:10.1056/NEJMoa2102383. PMID 33891380.
- ↑ "Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial". Lancet 397 (10273): 487–498. February 2021. doi:10.1016/S0140-6736(21)00125-2. PMID 33549193.
Further reading
- "Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis". BioDrugs 33 (4): 391–399. August 2019. doi:10.1007/s40259-019-00361-6. PMID 31172372.
 |  |
